bioAffinity Technologies earnings release, May 8, 2026

bioAffinity Technologies, Inc. (BIAF) · Form 8-K, Item 2.02 · Filed · SEC filing

Exhibit

99.1 bioAffinity

Technologies Reports First Quarter 2026 Results and Expanding Adoption and Clinical Usage of CyPath®

Lung

CyPath®

Lung cancer diagnostic unit sales rise 146% year-over-year

Growth expected to accelerate throughout 2026 as planned commercial initiatives seek to drive increasing awareness of CyPath®

Lung benefits

SAN

ANTONIO, Texas – May 8, 2026 – bioAffinity Technologies, Inc.

(Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, today reported financial results for the first quarter ended March 31, 2026.

Q1

2026 Highlights

Management

Commentary

“Our first quarter results demonstrate continued momentum for CyPath®

Lung in the marketplace. As more and more physicians adopt CyPath®

Lung and share their experiences with peers, we see the opportunity to expand our commercial reach and bridge the diagnostic gap between imaging and invasive procedures, especially when dealing with indeterminate nodules in high-risk patients,” said Maria Zannes, President and CEO of bioAffinity Technologies. “We are accelerating our marketing strategy to expand access to CyPath®

Lung and educate healthcare practitioners and patients alike about the need for accurate, objective information to better stratify risk and improve patient outcomes. On April 8, we hosted our first webinar featuring a panel of pulmonologists who shared how they use CyPath®

Lung in their diverse practices.”

Ms.

Zannes continued, “Physicians continue to share their case studies in which CyPath®

Lung has identified lung cancer as early as Stage 1A when it is most treatable and conversely in which a negative CyPath®

Lung result helped avoid unnecessary invasive procedures. We believe the growing number of case studies and our longitudinal clinical trial, supported by leading military and VA institutions, will lead to broader adoption of CyPath®

Lung as part of the standard of care.”

Ms.

Zannes concluded, “We are uniquely positioned to fulfill the need for an accurate, noninvasive diagnostic for lung cancer, particularly when imaging and risk models are inconclusive or turn out to be wrong. The remainder of 2026 will be focused on scaling commercial execution, expanding into new geographic markets, and driving increased utilization of CyPath®

Lung through continued physician engagement while also leveraging our flow cytometry and AI platform to advance our pipeline of diagnostics for serious or life-threatening lung diseases.”

First

Quarter 2026 Financial Results

Revenue for the quarter ended March 31, 2026, was $1.4 million. Revenue was primarily generated from patient service fees, histology services, and medical director fees.

Operating expenses for the first quarter of 2026 were $5.0 million, compared with $4.5 million in the first quarter of 2025.

Direct costs and expenses for the first quarter of 2026 were $0.9 million, down 32% from $1.4 million in the prior-year period, primarily due to targeted strategic actions implemented in March 2025. Research and development expenses decreased 5% year-over-year to $350,000, reflecting lower employee compensation and lab supply costs. Clinical development expenses rose to $334,000, driven by higher professional fees supporting the Company’s longitudinal clinical trial strategy.

Selling, general and administrative expenses were $3.2 million for the first quarter of 2026, up from $2.5 million in the same period last year.

The increase was primarily driven by higher employee compensation related to administrative and sales functions, reflecting the addition of personnel and support services to scale the commercialization of CyPath®

Lung.

Net loss for the quarter ended March 31, 2026, was $3.6 million, or $(0.81) per share, compared with a net loss of $2.7 million, or $(4.80) per share, for the first quarter of 2025.

Cash and cash equivalents as of March 31, 2026, were $3.1 million, compared with $6.4 million as of December 31, 2025.

About

CyPath®

Lung

CyPath®

Lung by bioAffinity Technologies is a noninvasive test designed to improve the early detection of lung cancer in patients at high risk for the disease. CyPath®

Lung uses advanced flow cytometry and proprietary artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy. CyPath®

Lung incorporates a fluorescent porphyrin that is preferentially taken up by cancer and cancer-related cells. In a clinical trial of high-risk patients, CyPath®

Lung demonstrated 92% sensitivity, 87% specificity, 88% accuracy and 99% negative predictive value (NPV) in detecting lung cancer in patients at high risk for the disease who had small indeterminate lung nodules less than 20 millimeters. The high NPV gives physicians greater confidence that a negative result is truly negative, potentially sparing patients from unnecessary invasive and costly procedures. CyPath®

Lung is marketed as a Laboratory Developed Test (LDT) and is not intended for use as a sole diagnostic tool and should be considered alongside other clinical findings.

About bioAffinity Technologies, Inc. bioAffinity

Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company’s first product, CyPath®

Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath®

Lung is marketed as a Laboratory Developed

Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. LDTs are overseen under the Clinical... (truncated)ore information, visit www.bioaffinitytech.com.

Forward-Looking

Statements

Financial statements

Income Statement

Three Months Ended March 31, — Unaudited Consolidated Statements of Operations

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Net Revenue1,351,5271,853,597
Operating expenses:Direct costs and expenses928,6361,367,860
Operating expenses:Research and development349,707367,386
Operating expenses:Clinical development334,040138,353
Operating expenses:Selling, general and administrative3,241,6022,452,549
Operating expenses:Depreciation and amortization114,518154,588
Operating expenses:Total operating expenses4,968,5034,480,736
Operating expenses:Loss from operations-3,616,976-2,627,139
Other income (expense):Interest income10,026542
Other income (expense):Interest expense-14,722-15,485
Other income (expense):Other income2
Other income (expense):Other expense-8,938-9,642
Other income (expense):Total other expense-13,634-24,583
Other income (expense):Net loss before provision for income taxes-3,630,610-2,651,722
Other income (expense):Income tax expense-8,695
Other income (expense):Net loss-3,630,610-2,660,417
Other income (expense):Net loss per common share, basic and diluted-0.81-4.8
Other income (expense):Weighted average common shares outstanding, basic and diluted4,494,752541,841

Balance Sheet

March 31, 2026 — Consolidated Balance Sheets

March 31, 2026 – (unaudited)December 31, 2025
Current assets:Cash and cash equivalents3,098,3666,449,782
Current assets:Accounts and other receivables, net685,235541,962
Current assets:Inventory77,88753,548
Current assets:Prepaid expenses and other current assets479,913519,916
Current assets:Total current assets4,341,4017,565,208
Non-current assets:Property and equipment, net246,849265,593
Non-current assets:Operating lease right-of-use asset, net651,430334,289
Non-current assets:Finance lease right-of-use asset, net586,048661,575
Non-current assets:Goodwill1,404,4861,404,486
Non-current assets:Intangible assets, net702,222716,806
Non-current assets:Other assets12,81612,815
Non-current assets:Total assets7,945,25210,960,772
Current liabilities:Accounts payable836,211761,901
Current liabilities:Accrued expenses2,033,9241,717,989
Current liabilities:Unearned revenue31,14042,405
Current liabilities:Operating lease liability, current portion142,303139,220
Current liabilities:Finance lease liability, current portion80,241139,490
Current liabilities:Notes payable, current portion61,141105,161
Current liabilities:Total current liabilities3,184,9602,906,166
Non-current liabilitiesOperating lease liability, net of current portion545,157202,878
Non-current liabilitiesFinance lease liability, net of current portion514,834532,759
Non-current liabilitiesNotes payable, net of current portion38,91541,313
Non-current liabilitiesTotal liabilities4,283,8663,683,116
Stockholders’ equity:Preferred stock, par value $0.001 per share; 20,000,000 shares authorized; 700 shares issued or outstanding at March 31, 2026, and December 31, 2025, respectively11
Stockholders’ equity:Common stock, par value $0.007 per share; 350,000,000 shares authorized; 4,498,675 shares issued and outstanding as of March 31, 2026, and December 31, 202531,46431,461
Stockholders’ equity:Additional paid-in capital75,814,59575,800,258
Stockholders’ equity:Accumulated deficit-72,184,674-68,554,064
Stockholders’ equity:Total stockholders’ equity3,661,3867,277,656
Stockholders’ equity:Total liabilities, and stockholders’ equity7,945,25210,960,772
Full release

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws.

Words such as “may,” “might,” “will,” “should,” “believe,” “expect,”

“anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,”

“plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company’s ability to obtain additional financing to fund operations, the Company’s limited operating history and history of net losses, the Company’s ability to achieve broader market acceptance of CyPath®

Lung, the Company’s dependence on key personnel, risks related to the regulatory environment for laboratory developed tests, the Company’s ability to maintain and protect its intellectual property, and the other factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and

8-K. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. While the Company believes these forward-looking statements are reasonable, readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The information in this release is provided only as of the date of this release, and the Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.

Contact bioAffinity Technologies

Julie

Anne Overton

Director of Communications investors@bioaffinitytech.com bioAffinity

Technologies, Inc.

Consolidated

Balance Sheets bioAffinity

Technologies, Inc.

Unaudited

Consolidated Statements of Operations

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · bioAffinity Technologies earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.